Table 1.
Clinical characteristics of MF patients included in the study. PV = polycythemia vera; ET= essential thrombocythemia.
| Patients’ Characteristics | Whole Cohort (n = 42) |
Ruxolitinib (n = 16) |
No Ruxolitinib (n = 26) |
|---|---|---|---|
| Median age at diagnosis (range) | 67 years (31–85) | 63.5 years (44–85) | 68.5 years (31–81) |
| Sex | |||
| Male | 21 (50%) | 9 (56%) | 12 (46%) |
| Female | 21 (50%) | 7 (44%) | 14 (54%) |
| Disease | |||
| Primary MF | 21/42 (50%) | 4/21 (19%) | 17/21 (81%) |
| Post-PV | 13/42 (31%) | 9/13 (69%) | 4/13 (31%) |
| Post-ET | 8/42 (19%) | 3/8 (37.5%) | 5/8 (62.5%) |
| IPSS SCORE | |||
| LOW | 11/42 (26.2%) | 4/11 (36%) | 7/11 (64%) |
| INT—1 | 15/42 (35.8%) | 6/15 (40%) | 9/15 (60%) |
| INT—2 | 8/42 (19%) | 4/8 (50%) | 4/8 (50%) |
| HIGH | 8/42 (19%) | 4/8 (50%) | 4/8 (50%) |
| Driver mutation | |||
| JAK2 | 29/42 (69.1%) | 15/29 (51.7%) | 14/29 (48.3%) |
| CALR | 9/42 (21.4%) | 1/9 (1.1%) | 8/9 (98.9%) |
| MPL | 1/42 (2.4%) | 0/1 (0%) | 1/1 (100%) |
| Triple negative | 3/42 (7.1%) | 0/3 (0%) | 3/3 (100%) |
| Time of exposition to ruxolitinib (range) | 26 months (4–48 ) | ||
| Spleen below costal margin, median (range) | 3 cm(0–20) | 3 cm (0–20) | 3.5 cm (0–20) |
| Hemoglobin g/dL, median (range) | 11.8 (6.2–15.5) | 11.6 (8.5–15.5) | 12.4 (6.2–15.3) |
| Platelets × 103/µL, median (range) | 306 (19–789) | 204 (19–724) | 362 (36–789) |
| WBC × 103/µL, median (range) | 7.39 (2.7–37.15) | 9.47 (3.5–37.15) | 6.7 (2.7–25.27) |
| Lymphocytes × 103/µL, median (range) | 1.55 (0.12–7.4) | 1.49 (0.51–7.4) | 1.6 (0.12–3.03) |
| Total protein g/dL, median (range) | 6.9 (5.8–8.5) | 7.05 (5.9–8.5) | 6.85 (5.8–7.8) |
| γ-Globulins (%), median (range) | 13 (5.8–23.9) | 13.2 (9–23.9) | 12.9 (5.8–22) |
| LDH U/L, median (range) | 415 (172–1430) | 377 (209–1019) | 498 (172–1430) |
Abbreviations: INT-1, Intermediate-1; INT-2, Intermediate-2; JAK2, Janus Kinase 2; CALR, Calreticulin; MPL, thrombopoietin receptor gene.